^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

MIR30E (MicroRNA 30e)

i
Other names: MIR30E, MicroRNA 30e, Hsa-MiR-30e-3p, Hsa-MiR-30e-5p, Hsa-Mir-30e, Hsa-Mir-30-P1b, MIRN30E, Mir-30e
Associations
Trials
21d
Exploring CSF microRNA signatures as diagnostic biomarkers in adult-type diffuse gliomas. (PubMed, Noncoding RNA Res)
Ingenuity Pathway Analysis (IPA) revealed that miR-16-5p and other miRNAs with seed AGCAGCA formed the largest interaction network in GBM, while disease enrichment analysis using Database for Annotation, Visualization, and Integrated Discovery (DAVID) confirmed that the 1000 predicted mRNA targets of DE-miRNAs in GBM were disease relevant. Collectively, these findings identify a robust panel of CSF-derived miRNAs capable of distinguishing IDH-mutant gliomas, GBM, and non-tumor states, supporting the potential of EV-miRNAs as minimally invasive biomarkers for the molecular characterization of diffuse gliomas.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MIR21 (MicroRNA 21) • MIR142 (MicroRNA 142) • MIR16 (MicroRNA 16) • MIR19B1 (MicroRNA 19b-1) • MIR27B (MicroRNA 27b) • MIR99A (MicroRNA 99a) • MIR150 (MicroRNA 150) • MIR195 (MicroRNA 195) • MIR26A1 (MicroRNA 26a-1) • MIR30A (MicroRNA 30a) • MIR30E (MicroRNA 30e)
|
IDH wild-type
1m
Molecular insights into NLRP3 inflammasome and miRNA modulation in oral cancer. (PubMed, Front Pharmacol)
Therefore, the NLRP3 inflammasome represents a key player in cancer development, and its regulation by miRNAs highlights its importance and clinical potential. This review summarizes mechanistic and clinical knowledge on the biology of NLRP3, highlights its dual role in cancer hallmarks, and discusses the therapeutic promise of targeting the NLRP3-miRNA axis in the management of oral cancer.
Review • Journal
|
IL18 (Interleukin 18) • MIR7 (MicroRNA 7) • IL1B (Interleukin 1, beta) • MIR223 (MicroRNA 223) • NLRP3 (NLR Family Pyrin Domain Containing 3) • MIR22 (MicroRNA 22) • MIR30E (MicroRNA 30e) • CASP1 (Caspase 1)
3ms
Extracellular microRNAs modulate human microglial function through TLR8. (PubMed, Front Immunol)
Extracellular delivery of miR-132-5p and miR-9-5p to co-cultures of iNeurons and iMGLs resulted in reduced neurite length. Our data establish that distinct CNS disease-associated miRNAs serve as signaling molecules for human microglia via TLR8, thereby controlling the diverse microglial functions and modulating the neuroinflammatory response.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TLR8 (Toll Like Receptor 8) • MIR132 (MicroRNA 132) • MIR340 (MicroRNA 340) • TLR7 (Toll Like Receptor 7) • MIR30E (MicroRNA 30e) • MIRLET7B (MicroRNA Let-7b)
5ms
Tumor-derived exosomes containing circ_0008039 promote the stemness of colorectal cancer cells by inhibiting ferroptosis. (PubMed, J Clin Biochem Nutr)
Mechanistic validation demonstrated that circ_0008039 regulated CRC cell proliferation, stemness maintenance and ferroptosis through the modulation of the miR-302e/SLC7A11 axis. The Circ_0008039/miR-302e/SLC7A11 axis plays a pivotal role in facilitating the proliferation and maintenance of stemness in CRC cells, while enhancing resistance to ferroptosis.
Journal
|
SOX2 • SLC7A11 (Solute Carrier Family 7 Member 11) • NANOG (Nanog Homeobox) • MIR30E (MicroRNA 30e) • TSG101 (Tumor Susceptibility 101)
5ms
Evaluation of Exosome-derived Small RNAs as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma Using Next-generation Sequencing. (PubMed, Ann Lab Med)
Multivariable Cox regression analyses, adjusting for potential prognostic factors such as sex, Eastern Cooperative Oncology Group performance status, and tumor size and stage, revealed that CARS1-AS1 (adjusted hazard ratio [HR] 0.33; 95% confidence interval [CI], 0.15-0.73; P =0.0061) and miR-142-5p (adjusted HR 0.79; 95% CI, 0.61-1.01; P = 0.0581) were associated with improved overall survival. We identified potential Ex-smRNA biomarkers involved in PDAC progression and prognosis that reflect key molecular alterations in PDAC and may serve as clinically relevant biomarkers for disease monitoring.
Journal • Next-generation sequencing
|
CCND1 (Cyclin D1) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • MIR142 (MicroRNA 142) • BACH1 (BTB Domain And CNC Homolog 1) • Let-7c (MicroRNA Let-7c) • MIR16 (MicroRNA 16) • MIR125A (MicroRNA 125a) • MIR30E (MicroRNA 30e) • MIR98 (MicroRNA 98)
6ms
A miR-30 Guided Molecular Profiling of Canine Osteosarcoma and Extraskeletal Osteosarcoma Reveals Non-Seed Regulatory Divergence. (PubMed, Cells)
MiR-30a and miR-30e exhibited the highest diagnostic power (LR+ 7.7 and 6.8, respectively), supporting their role as biomarkers. These results highlight a miR-30-centered regulatory axis with relevance for diagnosis and molecular stratification of canine osteogenic tumors.
Journal
|
MIR30B (MicroRNA 30b) • KPNA2 (Karyopherin Subunit Alpha 2) • MIR30A (MicroRNA 30a) • MIR30C • MIR30E (MicroRNA 30e) • RUNX2 (RUNX Family Transcription Factor 2)
6ms
The ETS transcription factor GABPA inhibits bladder cancer aggressiveness by repressing extracellular matrix deposition and mechanotransduction signaling. (PubMed, Cell Death Dis)
Collectively, GABPA inhibits P4HA2 expression and Col formation through the DICER1-miR30e axis, thereby repressing ECM deposition/stiffness and blocking mechanotransduction signaling, which consequently restrains BC aggressiveness. These findings unravel a novel role for GABPA in BC pathogenesis and have biological and therapeutic implications.
Journal
|
YAP1 (Yes associated protein 1) • DICER1 (Dicer 1 Ribonuclease III) • MIR30E (MicroRNA 30e) • P4HA2 (Prolyl 4-Hydroxylase Subunit Alpha 2)
6ms
MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung Cancer. (PubMed, Cancers (Basel))
Comparative expression analysis on tumor and matched normal tissues from surgically treated NSCLC patients confirmed their differential expression in clinical samples. In summary, we identified a signature of six miRNAs that are suppressed in NSCLC and may serve as a predictor of cisplatin response in NSCLC.
Journal
|
MIR34A (MicroRNA 34a-5p) • TGFB1 (Transforming Growth Factor Beta 1) • MIR497 (MicroRNA 497) • MIR26A1 (MicroRNA 26a-1) • MIR30E (MicroRNA 30e)
|
cisplatin
8ms
Analysis of the Expression Patterns of Tumor Necrosis Factor Alpha Signaling Pathways and Regulatory MicroRNAs in Astrocytic Tumors. (PubMed, Int J Mol Sci)
Our findings establish a multi-layered regulatory mechanism of TNF-α signaling in astrocytic tumors. These data highlight the TNF-α/IL-1β/MAP3K8 axis as a critical driver of glioma aggressiveness and a potential therapeutic target.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • MIR34A (MicroRNA 34a-5p) • IL1B (Interleukin 1, beta) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) • MAP2K7 (Mitogen-Activated Protein Kinase Kinase 7) • MIR30E (MicroRNA 30e)
1year
Reciprocal regulation between DNMT3A/3B and microRNAs miRs-299-3p/-30e is a causal factor for the downregulation of microRNAs targeting androgen receptor in prostate cancer. (PubMed, Heliyon)
Our study provides evidence that ectopic expression of miRs-30e and -299-3p restore the loss of expression of miRs-299-3p and -34c miRNAs mediated by DNMT-induced promoter hypermethylation. This study establishes a feedback regulation between AR targeting miRNAs and DNMTs in PCa cells and provides an insight into the mechanism of the aberrant expression of AR in advanced PCa that is potentially mediated through the downregulation of miRs-299-3p, -34c and -30e and stabilization of expression and activities of DNMTs.
Journal
|
DNMT3A (DNA methyltransferase 1) • MIR30E (MicroRNA 30e)